3.54
price down icon3.01%   -0.11
after-market After Hours: 3.65 0.11 +3.11%
loading
Aileron Therapeutics Inc stock is traded at $3.54, with a volume of 87,367. It is down -3.01% in the last 24 hours and up +40.48% over the past month. Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
See More
Previous Close:
$3.65
Open:
$3.6
24h Volume:
87,367
Relative Volume:
1.21
Market Cap:
$74.96M
Revenue:
-
Net Income/Loss:
$-12.94M
P/E Ratio:
-1.2465
EPS:
-2.84
Net Cash Flow:
$-13.83M
1W Performance:
-4.58%
1M Performance:
+40.48%
6M Performance:
-46.61%
1Y Performance:
+132.89%
1-Day Range:
Value
$3.2819
$3.65
1-Week Range:
Value
$2.86
$3.72
52-Week Range:
Value
$1.01
$7.42

Aileron Therapeutics Inc Stock (ALRN) Company Profile

Name
Name
Aileron Therapeutics Inc
Name
Phone
(737) 802-1989
Name
Address
12407 N. MOPAC EXPY., AUSTIN, MA
Name
Employee
3
Name
Twitter
@Aileron_org
Name
Next Earnings Date
2024-10-11
Name
Latest SEC Filings
Name
ALRN's Discussions on Twitter

Aileron Therapeutics Inc Stock (ALRN) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-24-17 Initiated BofA/Merrill Buy
Jul-24-17 Initiated Jefferies Buy
Jul-24-17 Initiated William Blair Outperform

Aileron Therapeutics Inc Stock (ALRN) Latest News

pulisher
Sep 28, 2024

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 13.4% in September - MarketBeat

Sep 28, 2024
pulisher
Sep 25, 2024

Alumis (NASDAQ:ALMS) Trading 4.8% Higher - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

Keeping an Eye on Alx Oncology Holdings Inc (ALXO) After Insider Trading Activity - Knox Daily

Sep 25, 2024
pulisher
Sep 25, 2024

Ready to Jump After Recent Trade: Alx Oncology Holdings Inc (ALXO) - SETE News

Sep 25, 2024
pulisher
Sep 24, 2024

ALXO stock touches 52-week low at $1.87 amid market challenges - Investing.com

Sep 24, 2024
pulisher
Sep 24, 2024

Alumis (NASDAQ:ALMS) Shares Gap Down to $11.86 - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Market Highlights: Alector Inc (ALEC) Ends on a Low Note at 5.45 - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

What is the investor’s view on Alx Oncology Holdings Inc (ALXO)? - US Post News

Sep 24, 2024
pulisher
Sep 23, 2024

Insider Sale Alert: Aldeyra Therapeutics Inc [ALDX] – Is it Time to sell? - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Alector (NASDAQ:ALEC) Shares Down 5.6% - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Alector (NASDAQ:ALEC) Shares Down 5.6% - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - Nasdaq

Sep 23, 2024
pulisher
Sep 23, 2024

Market Update: Alx Oncology Holdings Inc (ALXO) Sees Negative Movement, Closing at 2.07 - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Keith Johns Joins Allurion's Board Of Directors - MPO-mag

Sep 23, 2024
pulisher
Sep 23, 2024

HighVista Strategies LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Taking on analysts’ expectations and winning: Alumis Inc. (ALMS) - SETE News

Sep 23, 2024
pulisher
Sep 23, 2024

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - StockTitan

Sep 23, 2024
pulisher
Sep 23, 2024

Healius sells Lumus imaging unit to Affinity for USD 657M - Medical Buyer

Sep 23, 2024
pulisher
Sep 22, 2024

Australia Medical Diagnostics Firm Healius Sells Lumus to Affinity for $657 Million - BNN Bloomberg

Sep 22, 2024
pulisher
Sep 22, 2024

Renaissance Technologies LLC Sells 800 Shares of Alexander’s, Inc. (NYSE:ALX) - Defense World

Sep 22, 2024
pulisher
Sep 21, 2024

Alector (NASDAQ:ALEC) Stock Price Up 9% - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

1,959,896 Shares in Alumis Inc. (NASDAQ:ALMS) Bought by SR One Capital Management LP - MarketBeat

Sep 21, 2024
pulisher
Sep 20, 2024

Aileron Therapeutics Inc Inc. (ALRN) Price Performance: The Role of Supply and Demand - The InvestChronicle

Sep 20, 2024
pulisher
Sep 20, 2024

Closing Bell Recap: Aileron Therapeutics Inc (ALRN) Ends at 2.91, Reflecting a 9.81 Upturn - The Dwinnex

Sep 20, 2024
pulisher
Sep 19, 2024

Alector (NASDAQ:ALEC) Stock Price Up 9% - MarketBeat

Sep 19, 2024
pulisher
Sep 19, 2024

Altair Engineering: Rating Downgrade As Near-Term Upside Is Limited (NASDAQ:ALTR) - Seeking Alpha

Sep 19, 2024
pulisher
Sep 19, 2024

Alumis (NASDAQ:ALMS) Shares Down 2.6% - MarketBeat

Sep 19, 2024
pulisher
Sep 19, 2024

Alesi Surgical wins FDA clearance for smoke management device and lands new funding - Mass Device

Sep 19, 2024
pulisher
Sep 19, 2024

Alector, Inc. (NASDAQ:ALEC) Short Interest Down 5.7% in August - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Allurion Technologies Inc. (NYSE:ALUR) Short Interest Up 8.6% in August - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Australia's ALS tumbles on subdued half-year forecast - XM

Sep 18, 2024
pulisher
Sep 18, 2024

Market cap of Allarity Therapeutics Inc [ALLR] reaches 4.22M – now what? - The DBT News

Sep 18, 2024
pulisher
Sep 18, 2024

Alumis (NASDAQ:ALMS) Stock Price Up 5.3% - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Alexander's (NYSE:ALX) Hits New 52-Week High at $248.10 - MarketBeat

Sep 18, 2024
pulisher
Sep 18, 2024

In the Green: Alector Inc (ALEC) Closes at 5.64, Up/Down -0.70 from Previous Day - The Dwinnex

Sep 18, 2024
pulisher
Sep 18, 2024

Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter

Sep 18, 2024
pulisher
Sep 18, 2024

Is Alector Inc (ALEC) worth investing in despite its undervalued state? - US Post News

Sep 18, 2024
pulisher
Sep 18, 2024

Alector (NASDAQ:ALEC) Receives Overweight Rating from Cantor Fitzgerald - Defense World

Sep 18, 2024
pulisher
Sep 17, 2024

Alimera Sciences completes merger with ANI Pharmaceuticals - Investing.com India

Sep 17, 2024
pulisher
Sep 17, 2024

Altius Minerals (TSE:ALS) Price Target Raised to C$29.00 at Canaccord Genuity Group - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

Guggenheim raises PT on ANI Pharma after Alimera deal completion - XM

Sep 17, 2024
pulisher
Sep 16, 2024

Alumis (NASDAQ:ALMS) Reaches New 12-Month Low at $10.37 - MarketBeat

Sep 16, 2024
pulisher
Sep 16, 2024

Prepare Yourself for Liftoff: Alector Inc (ALEC) - SETE News

Sep 16, 2024
pulisher
Sep 16, 2024

ANI Pharmaceuticals completes acquisition of Alimera Sciences - TipRanks

Sep 16, 2024
pulisher
Sep 16, 2024

ANI Pharmaceuticals completes purchase of Alimera Sciences (NASDAQ:ALIM) - Seeking Alpha

Sep 16, 2024
pulisher
Sep 16, 2024

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences - GlobeNewswire

Sep 16, 2024
pulisher
Sep 16, 2024

ANI Pharmaceuticals initiates closing of acquisition of Alimera Sciences - TipRanks

Sep 16, 2024
pulisher
Sep 16, 2024

ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences - GlobeNewswire

Sep 16, 2024
pulisher
Sep 15, 2024

(ALEC) Trading Advice - Stock Traders Daily

Sep 15, 2024
pulisher
Sep 13, 2024

Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study - Zacks Investment Research

Sep 13, 2024
pulisher
Sep 03, 2024

University of Texas Texas AM Investment Management Co. Makes New Investment in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat

Sep 03, 2024

Aileron Therapeutics Inc Stock (ALRN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$358.35
price down icon 0.05%
$21.90
price up icon 4.86%
$224.51
price up icon 2.79%
$66.83
price up icon 1.64%
$118.77
price up icon 0.47%
$542.08
price up icon 1.11%
Cap:     |  Volume (24h):